Forde Keyslides
- Home
-
Archief
-
ASCO GU 2024
-
SABCS 2023
-
ESMO 2023
-
WCLC 2023
-
WCGIC 2023
-
Highlights Newsletter 1
- Podcast with Prof. Bruno Sangro about the four-year overall survival update from the phase III HIMALAYA study
- Podcast with Dr. Anna Dorothea Wagner about the integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER2-positive gastric cancer
- Podcast with Dr. Monica Niger about the clinical relevance and actionability of BRAF alterations in advanced biliary tract cancer
- Podcast with Marjolein Lansbergen about a transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort
- Highlights Newsletter 2
- Keyslides Newsletter 2
- Highlights Newsletter 3
-
Highlights Newsletter 1
-
ASCO 2023
- Highlights Newsletter 1
- Keyslides Newsletter 1
- Highlights Newsletter 2
- Keyslides Newsletter 2
- Highlights Newsletter 3
- Keyslides Newsletter 3
-
Highlights Newsletter 4
- Podcast with Prof. Dr. Lore Decoster about the highlights on lung cancer presented at ASCO 2023
- Podcast with Prof. Dr. Hans Prenen about the highlights on gastro-intestinal cancer presented at ASCO 2023
- Podcast with Dr. Willem Lybaert about the highlights on head and neck cancer presented at ASCO 2023
- Podcast with Prof. Dr. Bart Neyns about the highlights on melanoma presented at ASCO 2023
- Podcast with Prof. Dr. Kristof Vulsteke about the highlights on prostate, bladder and kidney cancer presented at ASCO 2023
-
ELCC 2023
- Highlights Newsletter 1
- Keyslides Newsletter 1
- Highlights Newsletter 2
- Keyslides Newsletter 2
-
Highlights Newsletter 3
- Podcast with dr. Jordi Remón-Masip about the safety and efficacy of osimertinib versus sequential gefitinib and osimertinib in patients with EGFR-mutant NSCLC
- Podcast with Prof. Niels Reinmuth about the patterns of response in metastatic NSCLC after 2 and 4 cycles of chemotherapy, alone or with durvalumab ± tremelimumab
- Podcast with Prof. Saadettin Kiliçkap about cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced NSCLC
-
ASCO GU 2023
- Highlights Newsletter 1
- Keyslides Newsletter 1
- Highlights Newsletter 2
- Keyslides Newsletter 2
-
Highlights Newsletter 3
- Podcast with Prof. Daniel Petrylak about pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer
- Podcast with Dr. Matthew D. Galsky about the efficacy and safety of atezolizumab plus platinum/gemcitabine for the first-line treatment of locally advanced or metastatic urothelial carcinoma
- Podcast with Dr. Alan H. Bryce about the survival outcomes of rucaparib vs. docetaxel or second-generation androgen pathway inhibitor therapy in mCRPC patients
- Podcast with Dr. Vadim Koshkin and Tanya Jindal about biomarkers of response to enfortumab vedotin in advanced urothelial carcinoma
-
SABCS 2022
- Highlights Newsletter 1
- Keyslides Newsletter 1
- Highlights Newsletter 2
- Keyslides Newsletter 2
- Highlights Newsletter 3
- Keyslides Newsletter 3
-
Highlights Newsletter 4
- Podcast with Prof. Sara Hurvitz about treatment with trastuzumab deruxtecan vs. trastuzumab emtansine in HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03
- Podcast with Dr. Judy Boughey about the impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer: Results from the Alliance trial
- Podcast with Prof. Mafalda Oliveira about different doses of camizestrant monotherapy vs. fulvestrant in advanced ER+/ HER2- breast cancer: Results from SERENA-2
- Podcast with Prof. Erica Mayer about fulvestrant, palbociclib, and avelumab treatment combinations for endocrine pre-treated ER+/HER2- metastatic breast cancer: Results from the PACE trial
- EBCC 2022
-
ESMO 2022
- Highlights Newsletter 1
- Keyslides Newsletter 1
- Highlights Newsletter 2
- Keyslides Newsletter 2
- Highlights Newsletter 3
- Keyslides Newsletter 3
- Highlights Newsletter 4
- Keyslides Newsletter 4
-
Highlights Newsletter 5
- Podcast with Prof. Anne Demols and Prof. Francesco Sclafani about the highlights from ESMO 2022 on gastrointestinal cancer
- Podcast with Prof. Christof Vulsteke about the highlights from ESMO 2022 on gynaecological cancer
- Podcast with Dr. Willem Lybaert about the highlights from ESMO 2022 on head and neck cancer
- Podcast with Prof. Lore Decoster about the highlights from ESMO 2022 on lung cancer
-
WCLC 2022
-
WCGIC 2022
-
EADO 2022
- Dr. Wissam discusses the highlights on adjuvant therapy in cutaneous melanoma
- Prof. Nikkels on the TELESPOT project: a Belgian teledermoscopy system in primary healthcare centres for early detection of skin cancer
- Prof. Hoeller about the potential role for adjuvant therapy in the treatment of intermediate risk melanoma patients
-
ASCO 2022
- Highlights Newsletter 1
- Keyslides Newsletter 1
- Highlights Newsletter 2
- Keyslides Newsletter 2
- Highlights Newsletter 3
- Keyslides Newsletter 3
-
Highlights Newsletter 4
- Dr. Kevin Punie talks us through some of the key data in the field of breast cancer
- Prof. Dr. Hans Prenen shares his highlights in the field of gastro-intestinal cancer
- Dr.Willem Lybaert discusses some of the key data in the field of head and neck cancer
- Prof. Dr. Lore Decoster will walk us through the highlights in thoracic oncology
- Dr. Daan De Maeseneer will share his highlights in the field of urogenital cancer
-
ELCC 2022
-
ASCO GU 2022
-
ASCO GI 2022
-
SABCS 2021
-
ESMO 2021
-
WCLC 2021
-
WCGIC 2021
-
ASCO 2021
-
ASCO GI 2021
-
ASCO GU 2021
-
WCLC 2020
-
ESMO 2020
-
WCGIC 2020
-
ASCO 2020
-
ESMO 2019
-
ASCO 2019
-
ASCO 2018
-
ESMO 2018
-
ESMO 2017
-
ASCO 2017
-
ESMO 2016
-
SABCS 2016
-
ECC 2015
-
ESMO 2014
-
ESMO 2012
- SABCS 2012
- EBCC 2012
-
SABCS 2011
-
ASCO GU 2024
-
ASCO 2024
-
WCGIC 2024
-
WCLC 2024
Speaker Patrick Forde
Patrick Forde, MD, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, USA
See: Presentation
Designed by Ariez International BV, The Netherlands